Jingxian Jiang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Jingxian Jiang has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
- Jingjing Wu
Department of Respiratory and Critical Care Medicine The First Affiliated Hospital of Nanjing Medical University Nanjing China
2 shared publications - Mao Huang
Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China
2 shared publications - Mingshun Zhang
Jiangsu Province Engineering Research Center of Antibody Drug, NHC Key Laboratory of Antibody Technique, Department of Immunology, Nanjing Medical University, Nanjing, China
2 shared publications - Ningfei Ji
Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China
2 shared publications - Qiyun Ma
Department of Respiratory and Critical Care Medicine The First Affiliated Hospital of Nanjing Medical University Nanjing China
2 shared publications - Xinyu Jia
Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China
2 shared publications
Latest Publications
- Open Access
- 13 March 2024
- Published by Wiley in Clinical and Translational Science
- Vol. 17 (3) , e13754
Plasma sCD146 is a potential biomarker for acute exacerbation of chronic obstructive pulmonary disease
This study examined the levels of soluble CD146 (sCD146) in plasma samples from patients with chronic obstructive pulmonary disease (COPD) and assessed the relationship between sCD146 and the severity of COPD. A total of 97 COPD patients were recruited from 20 medical centers in Jiangsu, China, including 13 stable subjects and 84 exacerbated subjects. The plasma sCD146 level in exacerbated subjects (28.77 ± 10.80 ng/mL) was significantly lower than that in stable subjects (38.84 ± 15.00 ng/mL). In the high sCD146 group, the proportion of subjects with modified Medical Research Council (mMRC) scores of 0–1 was higher, the proportion of subjects with the Global Initiative for Chronic Obstructive Lung Disease (GOLD) stage 4 was lower, and the proportion of subjects with ≥1 hospitalizations in the past year was lower. The plasma sCD146 level was negatively correlated with the COPD Assessment Test (CAT) score (r = −0.2664, p = 0.0087). Logistic regression analysis showed that sCD146 was an independent risk factor for acute exacerbation of COPD (AECOPD). Receiver operating characteristic (ROC) analysis suggested that sCD146 combined with sex, age, pulmonary function, and acute exacerbations in the past year had clinical value for the accurate identification of AECOPD, with an area under the ROC curve (AUC) of 0.908 (95% CI: 0.810–1.000, p < 0.001). In addition, there was a significant negative correlation between plasma sCD146 and S100A9 (r = −0.3939, p < 0.001).
- 13 March 2024
- Published by Wiley in Clinical and Translational Science
- Vol. 17 (3) , e13754
Open AccessPlasma sCD146 is a potential biomarker for acute exacerbation of chronic obstructive pulmonary disease
This study examined the levels of soluble CD146 (sCD146) in plasma samples from patients with chronic obstructive pulmonary disease (COPD) and assessed the relationship between sCD146 and the severity of COPD. A total of 97 COPD patients were recruited from 20 medical centers in Jiangsu, China, including 13 stable subjects and 84 exacerbated subjects. The plasma sCD146 level in exacerbated subjects (28.77 ± 10.80 ng/mL) was significantly lower than that in stable subjects (38.84 ± 15.00 ng/mL). In the high sCD146 group, the proportion of subjects with modified Medical Research Council (mMRC) scores of 0–1 was higher, the proportion of subjects with the Global Initiative for Chronic Obstructive Lung Disease (GOLD) stage 4 was lower, and the proportion of subjects with ≥1 hospitalizations in the past year was lower. The plasma sCD146 level was negatively correlated with the COPD Assessment Test (CAT) score (r = −0.2664, p = 0.0087). Logistic regression analysis showed that sCD146 was an independent risk factor for acute exacerbation of COPD (AECOPD). Receiver operating characteristic (ROC) analysis suggested that sCD146 combined with sex, age, pulmonary function, and acute exacerbations in the past year had clinical value for the accurate identification of AECOPD, with an area under the ROC curve (AUC) of 0.908 (95% CI: 0.810–1.000, p < 0.001). In addition, there was a significant negative correlation between plasma sCD146 and S100A9 (r = −0.3939, p < 0.001).
- Open Access
- 1 January 2024
- Published by XMLink in Allergy, Asthma & Immunology Research
- Vol. 16 (1) , 71-90
LincR-PPP2R5C Promotes Th2 Cell Differentiation Through PPP2R5C/PP2A by Forming an RNA–DNA Triplex in Allergic Asthma
Ji N, et al. Allergy Asthma Immunol Res. 2024 Jan;16(1):71-90. https://doi.org/10.4168/aair.2024.16.1.71
- 1 January 2024
- Published by XMLink in Allergy, Asthma & Immunology Research
- Vol. 16 (1) , 71-90
Open AccessLincR-PPP2R5C Promotes Th2 Cell Differentiation Through PPP2R5C/PP2A by Forming an RNA–DNA Triplex in Allergic Asthma
Ji N, et al. Allergy Asthma Immunol Res. 2024 Jan;16(1):71-90. https://doi.org/10.4168/aair.2024.16.1.71